Cas:904086-02-8 4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid manufacturer & supplier

Chemical Name:4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid

CAS.NO:904086-02-8

Synonyms:4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid

Molecular Formula:C₁₈H₁₉NO₄

Molecular Weight:313.34800

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:75.63000

Exact Mass:313.13100

LogP:4.47180

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid Use and application,4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzoic acid technical grade,usp/ep/jp grade.

Related News: Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. 9H-Cyclopenta[b]quinolin-9-imine, 4-hexadecyl-1,2,3,4-tetrahydro- manufacturers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 2-Cyclohexen-1-one, 6-(acetyloxy)-3,5,5-trimethyl-, (6S)- suppliers Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. N-(5,6-Bis-methylamino-pyrimidin-4-yl)-formamide vendor & factory Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments.,Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments.